Compound Spotlight Tesamorelin is the full 44-amino-acid sequence of human growth hormone-releasing hormone with one small chemical addition at the front end. That single change is enough to keep the molecule from being switched off within minutes, and it carried tesamorelin through phase 3 trials to an FDA approval, which almost nothing else in the
Compound Spotlight TB-500 is usually described as synthetic thymosin beta-4. It is not. Analytical laboratories that have examined TB-500 identify it as a seven-amino-acid peptide copied from one region of thymosin beta-4, with an acetyl group added to one end. That distinction decides which research actually applies to it. Quick summary TB-500 is Ac-LKKTETQ: residues
Compound Spotlight Sermorelin is the first 29 amino acids of a 44-amino-acid hormone. That shortened chain turned out to carry the hormone’s full growth hormone releasing activity, and it reached the US market as Geref. It later left the market, and the public record documents how. Quick summary A 29-amino-acid analogue of human growth hormone
Compound Spotlight Ipamorelin is five amino acids long and was designed to do one thing. Earlier growth hormone releasing peptides raised growth hormone, but they also pushed up ACTH and cortisol. Ipamorelin was the first compound in the class reported to release growth hormone with a selectivity close to that of the body’s own releasing
Compound Spotlight Hexarelin is a six-amino-acid peptide built to release growth hormone, and in early human studies it did that more strongly than GHRH itself. The more unusual part of its story came later, when researchers looking for its binding site in the heart found it attached to a receptor that has nothing to do
Compound Spotlight GHK-Cu began as an odd result in a liver-cell experiment and became one of the most studied small peptides in skin biology. It is three amino acids holding a single copper ion, and it occurs naturally in human blood. Most of what is known about it in people comes from skin research, not